Saturn V Capital Management as of June 30, 2025
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 24 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 8.9 | $22M | 207k | 106.12 | |
| Disc Medicine (IRON) | 8.5 | $21M | 396k | 52.96 | |
| Amylyx Pharmaceuticals (AMLX) | 8.5 | $21M | 3.3M | 6.41 | |
| Vaxcyte (PCVX) | 7.2 | $18M | 544k | 32.51 | |
| Cogent Biosciences (COGT) | 6.7 | $17M | 2.3M | 7.18 | |
| Celcuity (CELC) | 6.4 | $16M | 1.2M | 13.35 | |
| Cg Oncology (CGON) | 6.2 | $15M | 587k | 26.00 | |
| Xenon Pharmaceuticals (XENE) | 5.9 | $15M | 468k | 31.30 | |
| Dyne Therapeutics (DYN) | 5.6 | $14M | 1.5M | 9.52 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 5.6 | $14M | 291k | 47.20 | |
| Merus N V (MRUS) | 4.8 | $12M | 224k | 52.60 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 4.2 | $10M | 793k | 13.14 | |
| Lenz Therapeutics (LENZ) | 4.1 | $10M | 342k | 29.31 | |
| Neurocrine Biosciences (NBIX) | 3.0 | $7.3M | 58k | 125.69 | |
| Ocular Therapeutix (OCUL) | 2.7 | $6.8M | 729k | 9.28 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.7 | $6.6M | 38k | 172.60 | |
| Argenx Se Sponsored Adr (ARGX) | 2.3 | $5.7M | 10k | 551.22 | |
| Abivax Sa Sponsored Ads (ABVX) | 1.9 | $4.8M | 623k | 7.65 | |
| Syndax Pharmaceuticals (SNDX) | 1.9 | $4.7M | 501k | 9.37 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $4.0M | 221k | 18.11 | |
| Contineum Therapeutics Cl A (CTNM) | 0.5 | $1.3M | 319k | 3.97 | |
| Replimune Group (REPL) | 0.5 | $1.2M | 129k | 9.29 | |
| Kalvista Pharmaceuticals (KALV) | 0.3 | $710k | 63k | 11.30 | |
| Silence Therapeutics Ads (SLN) | 0.1 | $202k | 35k | 5.80 |
